Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. U.S. patent expiry tables. Information about our Innovative Medicine patent portfolio.

2024年11月20日 · 据其新闻稿，JNJ-2113是第一个选择性阻断IL-23受体的靶向口服肽，适用于12岁及以上患有中度至重度斑块状银屑病（PsO）的成人和青少年。 与安慰剂相比，每日一次icotrokinra在患有中度至重度斑块状银屑病的成人和青少年中显示出显著的皮肤清除率。

2024年3月12日 · 结果显示，JNJ-2113在患有中度至重度斑块状银屑病（PsO）的成人患者中保持了52周的高皮肤病变清除率。 根据新闻稿，JNJ-2113是旨在阻断IL-23R的首个在研靶向口服多肽。 2023年公布的FRONTIER 1研究的结果显示，在第16周，接受JNJ-2113治疗的患者中，达到银屑病面积与严重程度指数（PASI）改善至少75%的受试者的比例（PASI 75，主要终点）以及PASI 90和PASI 100的患者比例超过安慰剂组。 此次公布的FRONTIER 2研究的结果显示，接 …

2024年2月7日 · Investigational JNJ-2113 is the first targeted oral peptide designed to block the IL-23 receptor, 2 which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. 3,4 JNJ-2113 binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 ...

2023年3月8日 · 3月7日，Protagonist Therapeutics宣布其与强生旗下杨森制药公司合作开发的IL-23受体拮抗剂JNJ-2113治疗中重度斑块状银屑病的IIb期FRONTIER 1研究取得积极结果，达到主要终点。 FRONTIER 1是一项随机、多中心、双盲、安慰剂对照的IIb期研究，纳入的255例患者需每日3次或每日2次口服JNJ-2113，主要终点是16周时达到PASI-75（银屑病面积与严重程度指数改善至少75%）的患者比例。 结果显示，与安慰剂组相比，JNJ-2113不同剂量治疗组PASI-75患 …

2023年7月4日 · SPRING HOUSE, PENNSYLVANIA, July 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque ...

2023年7月4日 · Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

With an outcomes-based design 1 and reduced procedural complexity 2, it’s designed to meet previously unmet surgical needs in hip fracture treatment. The TFN-ADVANCED Nailing System is a part of the Advanced Nailing System from DePuy Synthes and has features that allow surgeons to address proximal femur fractures. The system includes:

JNJ-2113 (formerly PN-235) met the study's primary endpoint, with a statistically significantly higher proportion of adult patients with moderate-to-severe plaque psoriasis achieving PASI-75 in...

2024年3月9日 · In FRONTIER 2, JNJ-2113 maintained high rates of skin clearance through 52 weeks in adults with moderate-to-severe plaque PsO. 1 In the five JNJ-2113 treatment groups, as measured by the Psoriasis Area and Severity Index (PASI) a, response rates were maintained from Week 16 to Week 52, with the highest PASI 75 response observed in the 100 mg ...